NEW YORK ( TheStreet) -- CHANGE IN RATINGSAbiomed ( ABMD) was downgraded to Hold at TheStreet Ratings. Advanced Micro Devices ( AMD) was downgraded at UBS to Neutral from Buy with a $4 price target. Lower outlook on structural and competitive challenges. Aeropostale ( ARO) upgraded from Neutral to Buy at Bank of America/Merrill Lynch said. $18 price target. Risk/reward is more attractive following the recent selloff. CGI Group ( GIB) was upgraded to Buy at TheStreet Ratings. Cliffs Natural ( CLF) was downgraded at Credit Suisse from Neutral to Underperform. $30 price target. Company is leveraged to the dramatic fall in iron ore prices. Cornerstone OnDemand ( CSOD) was initiated with a Neutral rating, UBS said. $28 price target. High valuation and expectations. Expedia ( EXPE) was downgraded to Hold from Buy at Jefferies. $56 price target. Solid progress as new platform ramps up. FedEx ( FDX) was downgraded from Outperform to Market Perform at Wells Fargo. Estimates also cut, given weakness at Express. Guess ( GES) was downgraded to Hold at TheStreet Ratings. HSN ( HSNI) was downgraded from Buy to Hold at Wunderlich. $50 price target. Valuation call, based on macro growth concerns. Hartford Financial Services ( HIG) was downgraded to Hold by TheStreet Ratings. Eli Lilly ( LLY) was upgraded from Market Perform to Outperform, Bernstein said. $52 price target. Company has a solid late-stage pipeline and there's a better chance that solanezumab is approved for Alzheimer's. LinkedIn ( LNKD) was upgraded to Buy from Hold at Jeffries. $142 price target. Best play in online recruiting. Louisiana-Pacific ( LPX) was downgraded from Hold to Reduce at TD Securities. Valuation call, based on $12.50 price target. McKesson ( MCK) was upgraded from Neutral to Buy at Mizuho. $99 price target. Recent selloff appears overdone. Qlik Technologies ( QLIK) was upgraded from Equal-weight to Overweight at Morgan Stanley said. $28 price target. Recent survey suggests that demand could remain strong for the next two years. Time Warner ( TWX) was upgraded to Buy from Neutral at UBS. $50 price target. Better stability/visibility to EPS. ViroPharma ( VPHM) was initiated with a Buy rating at Deutsche Bank. $37 price target. HAE drug should be the company's main profit growth driver. Vitamin Shoppe ( VSI) was upgraded from Neutral to Buy at Bank of America/Merrill Lynch. $67 price target. Company can sustain healthy growth. Westinghouse ( WAB) was started with an Outperform rating at Credit Suisse. $99 price target. Company has multiple potential growth levers. Williams-Sonoma ( WSM) was upgraded from Hold to Buy at Deutsche Bank. $48 price target. Consistent sales growth is leading to higher margins.
STOCK COMMENTS / EPS CHANGES
Apple ( AAPL) target boosted at JP Morgan. Shares of AAPL now seen reaching $770, according to JP Morgan. iPhone and iPad can continue to grow ahead of expectations. Overweight rating. Amazon ( AMZN) numbers raised at Jefferies. Shares of AMZN now seen reaching $300, Jefferies said. Estimates also raised on superior growth. Buy rating. Campbell Soup ( CPB) numbers raised at UBS. Shares of CPB now seen reaching $36, UBS said. Estimates also raised on higher medium term revenue trends. Neutral rating. eBay ( EBAY) numbers raised at Jefferies. Shares of EBAY now seen reaching $56, Jefferies said. Estimates also raised on turnaround in core biz and upside from PayPal. Buy rating. FedEx ( FDX) numbers cut at UBS. Shares of FDX now seen reaching $110, UBS said. Estimates also lowered on weak Express revenue growth. Buy rating. Finisar ( FNSR) numbers lowered at Citigroup. Shares of FNSR now seen reaching $17, Citigroup said. Estimates also lowered on soft guidance. Buy rating. Francesca's ( FRAN) estimates, target raised at Keybanc. Shares of FRAN now seen reaching $38, according to Keybanc. Estimates also increased, as higher sales are driving margin expansion. Buy rating. Halliburton ( HAL) estimates, target cut at SocGen. HAL estimates were reduced through 2014, Societe Generale said. Company is seeing slower drilling activity in North America. Buy rating and new $50 price target. J.C. Penny ( JCP) estimates lowered at Oppenheimer. JCP estimates lowered through 2013, Oppenheimer said. Turnaround continues to take shape. Outperform rating.